|
|
|
|
Lifecore Biomedical Inc (NASDAQ: LFCR) |
|
Price: $6.4250
$0.18 
2.800%
|
| Day's High:
| $6.425
| Week Perf:
| 12.42 %
|
| Day's Low: |
$ 6.25 |
30 Day Perf: |
-2.21 % |
| Volume (M): |
57 |
52 Wk High: |
$ 7.99 |
| Volume (M$): |
$ 368 |
52 Wk Avg: |
$5.89 |
| Open: |
$6.33 |
52 Wk Low: |
$3.68 |
|
|
| Market Capitalization (Millions $) |
238 |
| Shares
Outstanding (Millions) |
37 |
| Employees |
209 |
| Revenues (TTM) (Millions $) |
131 |
| Net Income (TTM) (Millions $) |
-49 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
11 |
Lifecore Biomedical Inc
Company Address: 3515 Lyman Boulevard Chaska, 55318 MN
Company Phone Number: 368-4300 Stock Exchange / Ticker: NASDAQ LFCR
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Contract
Published Thu, Dec 19 2024 12:01 PM UTC
Lifecore Biomedical and Nirsum Labs Collaborate on Development of Innovative Opioid Use Disorder Treatment Lifecore Biomedical, a renowned contract development and manufacturing organization (CDMO), has recently been selected by Nirsum Labs to provide comprehensive development and manufacturing services for NRS-033, a novel treatment aimed at addressing opioid use disorder. ...
|
| Management Changes
Published Mon, Nov 4 2024 12:00 PM UTC
Lifecore Biomedical Enhances Its Operational Foundation with Strategic Leadership Appointment and Capital InfusionIn a series of strategic maneuvers aimed at bolstering its operational capabilities and financial standing, Lifecore Biomedical Inc. has taken significant steps to navigate a challenging landscape within the life sciences sector. Recently, the company appointed ...
|
| Financing Agreement
Published Fri, Oct 4 2024 11:20 AM UTC
Lifecore Biomedical Navigates Financial Challenges with Strategic PIPE Investment Despite Recent LossesIn a bold move to bolster its balance sheet and reinforce operational capabilities, Lifecore Biomedical Inc. announced a successful Private Investment in Public Equity (PIPE) transaction, raising $24.3 million. This infusion of capital comes at a critical juncture for the ...
|
| Announcement
Published Thu, Sep 19 2024 1:00 AM UTC
for CSIMarket.com In recent months, numerous class action lawsuits have been initiated against various companies, including Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYSE: SPIR), DexCom, Inc. (NASDAQ: DXCM), Arbor Realty Trust, Inc. (NYSE: ABR), and Oddity Tech (NASDAQ: ODD). These actions, led by notable investor rights law firms such as Bragar Eagel...
|
| Announcement
Published Wed, Sep 11 2024 1:00 AM UTC
New York, September 10, 2024 - Bragar Eagel & Squire, P.C., a law firm recognized nationwide for its expertise in shareholder rights, has issued a reminder to investors regarding pending class action lawsuits on behalf of stockholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYSE: SPIR), Oddity Tech (NASDAQ: ODD), and Arbor Realty Trust, Inc. (NYSE: A...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.39 $ |
| Revenues (TTM) |
3.53 $
|
| Cash Flow (TTM) |
0.06 $ |
| Cash |
0.15 $
|
| Book Value |
0.06 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.39 $
|
| Revenues (TTM) |
3.53 $ |
| Cash Flow (TTM) |
0.06 $ |
| Cash |
0.15 $
|
| Book Value |
0.06 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| CDMO |
|
 59.66 % |
of total Revenue |
| HA manufacturing |
|
41.23 % |
of total Revenue |
| Revenues recognized over time |
|
15.8 % |
of total Revenue |
| Revenues recognized at a point in time |
|
85.09 % |
of total Revenue |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
